SHS el al. provide €7m cash boost for LipoFIT

LipoFIT has been awarded the funding to help launch its diagnostic technology into the market and ensure it continues to expand within the areas of human diagnostics, biogas and plant analytics. The Germany-based company aims to become the market leader in Nuclear Magnetic Resonance (NMR)-based analytics.

A private investor also subscribed to the round, which follows on from a €4m round of series-A financing from the three lead investors in December 2009. At that time, the business employed 10 people and the backers took an almost 50% stake.

Since then, LipoFIT has impressed SHS in particular by demonstrating the "ingenuity" of its founders, its international management skills and industry expertise. The investor believes the firm has the opportunity to initiate a change of thinking in the field of NMR-based analytics.

SHS participated in the round using SHS III and parallel fund SHS GT II. SHS III launched in 2006 and raised a total of €50m.

Company
LipoFIT Analytic was established in April 2004 as a spin-off of the Institute for Biophysics at the University of Regensburg. Developed by researchers, the company's technology uses samples of bodily fluids to analyse patients' metabolisms and assess their risk of atherosclerosis.

The firm has grown to become the largest user of NMR analytics in Europe, boasting a database of approximately 200,000 clinical samples. Its clients include pharmaceuticals companies and university clinics.

People
Bernhard Schirmers, founder and partner, invested on behalf of SHS. Biophysicists Hans Robert Kalbitzer, Werner Kremer and Fritz Huber are the co-founders of LipoFIT. Huber is managing director and Volker Pfahlert is the company's COO.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Expansion
• Germany